Scientific Name: Degarelix
Brand Name: Firmagon
Company Owner: Not Available
Mechanism Of Action Degarelix competitively inhibits GnRH receptors in the pituitary gland, preventing the release of luteinizing hormone (LH) and follicle stimulating hormone. Reduced LH suppresses testosterone release, which slows the growth and reduces the size of prostate cancers.
Description of the Drug: Degarelix is a GnRH receptor antagonist used in the management of advanced prostate cancer.
Protein Data Bank: Not Available
Source: DrugBank Online – Retrieved 2023-01-23 from